GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.
THREE IChemE members have been honoured for their contributions to the chemical engineering profession in the King’s New Year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback